Suchergebnisse - "Epirubicin administration & dosage"
-
1
Autoren: et al.
Quelle: Jensen, M-B, Balslev, E, Knoop, A S, Tuxen, M K, Højris, I, Jakobsen, E H, Cold, S, Danø, H, Glavicic, V, Kenholm, J & Ejlertsen, B 2024, ' Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer : Final Analysis of the Randomized DBCG 07-READ Trial ', Journal of Clinical Oncology, vol. 43, no. 4, pp. 373-380 . https://doi.org/10.1200/JCO.24.00836
Jensen, M B, Balslev, E, Knoop, A S, Tuxen, M K, Højris, I, Jakobsen, E H, Cold, S, Danø, H, Glavicic, V, Kenholm, J & Ejlertsen, B 2025, 'Adjuvant Docetaxel and Cyclophosphamide with or Without Epirubicin for Early Breast Cancer : Final Analysis of the Randomized DBCG 07-READ Trial', Journal of Clinical Oncology, vol. 43, no. 4, pp. 373-380. https://doi.org/10.1200/JCO.24.00836Schlagwörter: Adult, Docetaxel/administration & dosage, Epirubicin/administration & dosage, Breast Neoplasms, Docetaxel, Middle Aged, Disease-Free Survival, Cyclophosphamide/administration & dosage, Breast Neoplasms/drug therapy, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cyclophosphamide, Adjuvant, Epirubicin, Aged
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39442040
https://curis.ku.dk/ws/files/430094059/Adjuvant_Docetaxel.pdf
https://portal.findresearcher.sdu.dk/da/publications/27b797ca-a9fe-4f45-af0e-b7c36607686a
https://doi.org/10.1200/JCO.24.00836
https://pure.au.dk/portal/en/publications/8f0d7f02-fcc1-4c1c-9484-81b67d6577ab
https://doi.org/10.1200/JCO.24.00836
http://www.scopus.com/inward/record.url?scp=85208218487&partnerID=8YFLogxK -
2
Autoren: et al.
Relation: Cancer Investigation; https://iris.unil.ch/handle/iris/98932; serval:BIB_53575370165E; A1993KV59300006; 8462014
-
3
Autoren: et al.
Schlagwörter: Adenocarcinoma/drug therapy, Adenocarcinoma/pathology, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cisplatin/administration & dosage, Epirubicin/administration & dosage, Female, Fluorouracil/administration & dosage, Humans, Male, Middle Aged, Quality of Life, Stomach Neoplasms/drug therapy, Stomach Neoplasms/pathology, Taxoids/administration & dosage, Treatment Outcome
Relation: Journal of Clinical Oncology; 1527-7755[electronic]; https://iris.unil.ch/handle/iris/77628; serval:BIB_20BB1386B9CA; 000248744000008
-
4
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Adult, Aged, Amenorrhea, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Cyclophosphamide/administration & dosage, Disease-Free Survival, Dose-Response Relationship, Drug, Epirubicin/administration & dosage, Female, Granulocyte Colony-Stimulating Factor/administration & dosage, Humans, Middle Aged, Neoplasms, Hormone-Dependent/drug therapy, Hormone-Dependent/metabolism, Receptors, Estrogen/biosynthesis, Recombinant Proteins, Stem Cell Transplantation, Survival Rate, Tamoxifen/administration & dosage, Treatment Outcome
Relation: Annals of Oncology; https://iris.unil.ch/handle/iris/193641; serval:BIB_CD05346CE716; 000268806700007
-
5
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Adenocarcinoma/drug therapy, Adenocarcinoma/surgery, Adult, Aged, Antineoplastic Agents/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Chemotherapy, Adjuvant, Clinical Trials, Phase III as Topic, Combined Modality Therapy, Disease-Free Survival, Doxorubicin/administration & dosage, Epirubicin/administration & dosage, Female, Fluorouracil/administration & dosage, Humans, Male, Methotrexate/administration & dosage, Middle Aged, Randomized Controlled Trials as Topic, Stomach Neoplasms/drug therapy, Stomach Neoplasms/surgery, Survival Analysis
Relation: Annals of Oncology; https://iris.unil.ch/handle/iris/158752; serval:BIB_A20260C65C6B; 000234965100014
-
6
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Adult, Aged, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Breast Neoplasms/drug therapy, Breast Neoplasms/mortality, Chemotherapy, Adjuvant, Cyclophosphamide/administration & dosage, Disease-Free Survival, Doxorubicin/administration & dosage, Drug Administration Schedule, Epirubicin/administration & dosage, Female, Fluorouracil/administration & dosage, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis/pathology, Methotrexate/administration & dosage, Middle Aged, Neoplasm Recurrence, Local/epidemiology, Receptors, Estrogen/metabolism, Tamoxifen/therapeutic use
Relation: Annals of Oncology; https://iris.unil.ch/handle/iris/149769; serval:BIB_7B605F3478F7; 000249559600008
-
7
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Brain Neoplasms/chemically induced, Brain Neoplasms/epidemiology, Brain Neoplasms/mortality, Brain Neoplasms/pathology, Breast Neoplasms/drug therapy, Breast Neoplasms/pathology, Disease Progression, Docetaxel, Epirubicin/administration & dosage, Epirubicin/adverse effects, Female, Humans, Incidence, Liver Neoplasms/secondary, Middle Aged, Paclitaxel/administration & dosage, Paclitaxel/adverse effects, Paclitaxel/analogs & derivatives, Receptor, ErbB-2/analysis, Receptors, Estrogen/analysis, Retrospective Studies, Taxoids
Relation: Annals of Oncology; https://iris.unil.ch/handle/iris/142535; serval:BIB_D17DC3B0ECEE; 000167806000019
-
8
Autoren: et al.
Weitere Verfasser: et al.
Schlagwörter: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms/drug therapy, Breast Neoplasms/mortality, Chemotherapy, Adjuvant, Cyclophosphamide/administration & dosage, Doxorubicin/administration & dosage, Epirubicin/administration & dosage, Female, Follow-Up Studies, Humans, Lymph Nodes/pathology, Lymphatic Metastasis, Middle Aged, Premenopause, Receptors, Estrogen/analysis, Progesterone/analysis, Risk Assessment, Survival Analysis, Survivors, Tamoxifen/therapeutic use
Relation: Breast Cancer Research and Treatment; https://iris.unil.ch/handle/iris/142870; serval:BIB_D3769B87B898; 000261951100016
-
9
Autoren: et al.
Quelle: Breast Cancer Res Treat
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, 'Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391–400. https://doi.org/10.1007/s10549-018-4918-4
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, ' Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study ', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391–400 . https://doi.org/10.1007/s10549-018-4918-4
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, 'Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391-400. https://doi.org/10.1007/s10549-018-4918-4
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, ' Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study ', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391-400 . https://doi.org/10.1007/s10549-018-4918-4Schlagwörter: RNA, Messenger/genetics, Adult, Epirubicin/administration & dosage, Breast Neoplasms, Biomarkers, Pharmacological, Disease-Free Survival, Neoplastic/drug effects, 03 medical and health sciences, 0302 clinical medicine, Breast Neoplasms/drug therapy, Neoplasm Proteins/genetics, Humans, Prospective Studies, RNA, Messenger, Precision Medicine, Aged, Epirubicin, Proportional Hazards Models, Retrospective Studies, Pharmacological, Precision medicine, Middle Aged, Clinical Trial, Neoplasm Proteins, 3. Good health, Gene Expression Regulation, Neoplastic, Predictive biomarker, Gene Expression Regulation, Gene Expression Regulation, Neoplastic/drug effects, Disease Progression, RNA, Messenger/genetics, Advanced breast cancer, Female, Biomarkers
Dateibeschreibung: application/pdf
Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s10549-018-4918-4.pdf
https://pubmed.ncbi.nlm.nih.gov/30099635
https://vbn.aau.dk/da/publications/predicting-efficacy-of-epirubicin -by-a-multigene-assay-in-advance
https://link.springer.com/content/pdf/10.1007/s10549-018-4918-4.pdf
https://link.springer.com/article/10.1007/s10549-018-4918-4
https://europepmc.org/article/MED/30099635
https://link.springer.com/article/10.1007/s10549-018-4918-4/fulltext.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208899
https://pure.au.dk/ws/files/167672692/Buhl2018_Article_PredictingEfficacyOfEpirubicin.pdf
https://curis.ku.dk/ws/files/222252352/Buhl2018_Article_PredictingEfficacyOfEpirubicin.pdf
https://findresearcher.sdu.dk:8443/ws/files/146451348/Buhl2018_Article_PredictingEfficacyOfEpirubicin.pdf -
10
Autoren: et al.
Quelle: Claassen, Y H M, Hartgrink, H H, Dikken, J L, de Steur, W O, van Sandick, J W, van Grieken, N C T, Cats, A, Trip, A K, Jansen, E P M, Meershoek-Klein Kranenbarg, W M, Braak, J P B M, Putter, H, van Berge Henegouwen, M I, Verheij, M & van de Velde, C J H 2018, 'Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial', European Journal of Surgical Oncology, vol. 44, no. 5, pp. 613-619. https://doi.org/10.1016/j.ejso.2018.02.004
European Journal of Surgical Oncology, 44, 5, pp. 613-619Schlagwörter: Postoperative Complications/epidemiology, Adult, Male, Surgical morbidity, Epirubicin/administration & dosage, Anastomotic Leak, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Risk Factors, Gastrectomy, Antineoplastic Combined Chemotherapy Protocols, Gastric cancer surgery, Humans, Organoplatinum Compounds/administration & dosage, Mortality, Capecitabine, Randomized Controlled Trials as Topic, Aged, Epirubicin, Aged, 80 and over, Stomach Neoplasms/therapy, Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences, Induction Chemotherapy, Middle Aged, Surgical mortality, Neoadjuvant Therapy, 3. Good health, Oxaliplatin, Esophagectomy, Logistic Models, Capecitabine/administration & dosage, Anastomotic Leak/epidemiology, Radiation Oncology - Radboud University Medical Center, Multivariate Analysis, Splenectomy, Lymph Node Excision, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cisplatin, Cisplatin/administration & dosage
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/29503129
https://research.vumc.nl/en/publications/surgical-morbidity-and-mortality-after-neoadjuvant-chemotherapy-i
https://pubmed.ncbi.nlm.nih.gov/29503129/
https://europepmc.org/article/MED/29503129
https://www.sciencedirect.com/science/article/abs/pii/S074879831830297X
https://www.ncbi.nlm.nih.gov/pubmed/29503129
https://core.ac.uk/display/159753016
https://research.vumc.nl/en/publications/b1c5c7f6-78a4-4d68-873d-02b42737fe2c
https://hdl.handle.net/1887/95505
https://pure.amsterdamumc.nl/en/publications/bde8ef49-de14-4d98-b8fc-9f8bca8e0f60
https://doi.org/10.1016/j.ejso.2018.02.004
https://hdl.handle.net/2066/193644
https://pure.au.dk/portal/en/publications/325d548a-81bc-4cd1-bcce-b31482dd0f26
https://doi.org/10.1016/j.ejso.2018.02.004 -
11
Autoren: et al.
Quelle: Journal of Clinical Oncology. 36:968-974
Schlagwörter: Adult, erbB-2 - biosynthesis, Double-blind method, Receptor, ErbB-2, Epirubicin - administration & dosage, Breast Neoplasms, Docetaxel - administration & dosage, Docetaxel, Cyclophosphamide - adverse effects, Breast neoplasms - pathology, Young Adult, 03 medical and health sciences, 0302 clinical medicine, adjuvant, Double-Blind Method, Trastuzumab - adverse effects, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Biosimilar pharmaceuticals - adverse effects, Middle aged, Biosimilar Pharmaceuticals, Cyclophosphamide, Aged, Epirubicin, Cyclophosphamide - administration & dosage, Epirubicin - adverse effects, Breast neoplasms - drug therapy, Middle Aged, Trastuzumab, Breast neoplasms - surgery, Neoadjuvant Therapy, 3. Good health, Fluorouracil - administration & dosage, Trastuzumab - administration & dosage, Young adult, Antineoplastic combined chemotherapy protocols - therapeutic use, Antineoplastic combined chemotherapy protocols - adverse effects, Chemotherapy, Adjuvant, Breast neoplasms - enzymology, Neoadjuvant therapy, Biosimilar pharmaceuticals - administration & dosage, Female, Fluorouracil, Docetaxel - adverse effects, Fluorouracil - adverse effects, Receptor
-
12
Autoren: et al.
Quelle: European Journal of Cancer. 93:19-27
Schlagwörter: Adult, Survival rate, Double-blind method, Adolescent, Epirubicin - administration & dosage, Breast Neoplasms, Docetaxel - administration & dosage, Follow-up studies, Docetaxel, Breast neoplasms - pathology, 03 medical and health sciences, 0302 clinical medicine, adjuvant, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Middle aged, Biosimilar Pharmaceuticals, Cyclophosphamide, Neoadjuvant therapy - mortality, Aged, Epirubicin, Cyclophosphamide - administration & dosage, Breast neoplasms - immunology, Breast neoplasms - mortality, Breast neoplasms - drug therapy, Middle Aged, Trastuzumab, Prognosis, Neoadjuvant Therapy, 3. Good health, Survival Rate, Fluorouracil - administration & dosage, Trastuzumab - administration & dosage, Young adult, Antineoplastic combined chemotherapy protocols - therapeutic use, Chemotherapy, Adjuvant, Biosimilar pharmaceuticals - administration & dosage, Female, Fluorouracil, Follow-Up Studies
Zugangs-URL: http://www.ejcancer.com/article/S0959804918300868/pdf
https://pubmed.ncbi.nlm.nih.gov/29448072
https://www.sciencedirect.com/science/article/pii/S0959804918300868
https://europepmc.org/article/MED/29448072
https://www.ncbi.nlm.nih.gov/pubmed/29448072
https://pubmed.ncbi.nlm.nih.gov/29448072/
https://snucm.elsevierpure.com/en/publications/a-phase-iii-study-comparing-sb3-a-proposed-trastuzumab-biosimilar
https://www.sciencedirect.com/science/article/abs/pii/S0959804918300868 -
13
Autoren: et al.
Quelle: Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer : DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, 'Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646. https://doi.org/10.1200/JCO.2017.72.3494Schlagwörter: Adult, Clinical Trial, Phase III, Epirubicin/administration & dosage, Breast Neoplasms, Docetaxel, Breast Neoplasms/genetics, Disease-Free Survival, Cyclophosphamide/administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Antigens, Neoplasm, Ductal, Antineoplastic Combined Chemotherapy Protocols, Journal Article, Chemotherapy, Humans, Antigens, Poly-ADP-Ribose Binding Proteins, Cyclophosphamide, Adjuvant, Mastectomy, Aged, Epirubicin, Neoplasm/genetics, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carcinoma, Carcinoma, Ductal, Breast, Middle Aged, Intention to Treat Analysis, 3. Good health, Breast/genetics, Survival Rate, Multicenter Study, DNA-Binding Proteins, Taxoids/administration & dosage, DNA Topoisomerases, Type II, Type II/genetics, Chemotherapy, Adjuvant, Randomized Controlled Trial, Taxoids, Female, Neoplasm Grading, Menopause, DNA Topoisomerases, DNA-Binding Proteins/genetics, Follow-Up Studies
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/28661759
https://portal.findresearcher.sdu.dk/da/publications/554fdc3f-7466-45b9-ab88-4f94228c0684
https://pure.au.dk/portal/en/publications/f83e6b9c-eab9-4ea8-9e27-78bbaa6b2632
https://doi.org/10.1200/JCO.2017.72.3494
http://www.scopus.com/inward/record.url?scp=85028706744&partnerID=8YFLogxK -
14
Autoren: et al.
Quelle: Lancet. Oncology, Vol. 17, No 12 (2016) pp. 1697-1708
Schlagwörter: Adult, Male, Esophageal Neoplasms, Medizin, Leucovorin, Stomach Neoplasms / drug therapy, Docetaxel, Adenocarcinoma / pathology, Adenocarcinoma, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Humans, Esophageal Neoplasms / pathology, Esophageal Neoplasms / surgery, Taxoids / administration & dosage, Aged, Epirubicin, Esophageal Neoplasms / drug therapy, ddc:617, Leucovorin / administration & dosage, Adenocarcinoma / surgery, Middle Aged, Neoadjuvant Therapy, 3. Good health, Adenocarcinoma / drug therapy, Female, Taxoids, Esophagogastric Junction, Cisplatin, Stomach Neoplasms / pathology, Cisplatin / administration & dosage, Epirubicin / administration & dosage, Stomach Neoplasms / surgery
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/27776843
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/supplemental
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext
https://www.download.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext
https://europepmc.org/article/MED/27776843
http://www.ncbi.nlm.nih.gov/pubmed/27776843
https://archive-ouverte.unige.ch/unige:158705 -
15
Autoren: et al.
Quelle: Eckhoff, L, Feddersen, S, Knoop, A, Ewertz, M & Bergmann, T K 2015, ' Docetaxel-induced neuropathy : A pharmacogenetic case-control study of 150 women with early-stage breast cancer ', Acta Oncologica, vol. 54, no. 4, pp. 535-542 . https://doi.org/10.3109/0284186X.2014.969846
Schlagwörter: Adult, ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Peripheral Nervous System Diseases/chemically induced, Epirubicin/administration & dosage, Antineoplastic Agents, Breast Neoplasms, Docetaxel, Cyclophosphamide/administration & dosage, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Breast Neoplasms/drug therapy, Genetic, Antineoplastic Combined Chemotherapy Protocols, Confidence Intervals, Odds Ratio, Humans, ATP Binding Cassette Transporter, Subfamily B/genetics, Polymorphism, Cyclophosphamide, Alleles, Aged, Epirubicin, Polymorphism, Genetic, Middle Aged, Subfamily B/genetics, Antineoplastic Agents/administration & dosage, 3. Good health, Oxidative Stress, Taxoids/administration & dosage, Glutathione S-Transferase pi, Haplotypes, Glutathione S-Transferase pi/genetics, Case-Control Studies, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Zugangs-URL: https://figshare.com/articles/journal_contribution/Docetaxel_induced_neuropathy_A_pharmacogenetic_case_control_study_of_150_women_with_early_stage_breast_cancer/1569654/1/files/2352236.pdf
https://pubmed.ncbi.nlm.nih.gov/25383449
https://cogentoa.tandfonline.com/doi/full/10.3109/0284186X.2014.969846
https://www.tandfonline.com/doi/full/10.3109/0284186X.2014.969846
https://portal.findresearcher.sdu.dk/da/publications/docetaxel-induced-neuropathy-a-pharmacogenetic-case-control-study
https://www.ncbi.nlm.nih.gov/pubmed/25383449
https://portal.findresearcher.sdu.dk/da/publications/1092692a-fce1-40d7-9b9e-61ae2081bf5e
https://doi.org/10.3109/0284186X.2014.969846
https://portal.findresearcher.sdu.dk/da/publications/1092692a-fce1-40d7-9b9e-61ae2081bf5e -
16
Autoren: et al.
Quelle: Eckhoff, L, Knoop, A, Jensen, M B & Ewertz, M 2015, ' Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors ', European Journal of Cancer, vol. 51, no. 3, pp. 292-300 . https://doi.org/10.1016/j.ejca.2014.11.024
Schlagwörter: Adult, Peripheral Nervous System Diseases/chemically induced, Epirubicin/administration & dosage, Breast Neoplasms, Docetaxel, Cyclophosphamide/administration & dosage, Young Adult, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Breast Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Humans, Longitudinal Studies, Survivors, Cyclophosphamide, Aged, Epirubicin, Chemotherapy-induced peripheral neuropathy, 2. Zero hunger, Peripheral Nervous System Diseases, Middle Aged, Survivors/statistics & numerical data, 3. Good health, Taxoids/administration & dosage, Quality of Life, Female, Taxoids, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Self Report
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/25541155
https://europepmc.org/article/MED/25541155
https://www.sciencedirect.com/science/article/abs/pii/S0959804914011496
http://findresearcher.sdu.dk/portal/da/publications/persistence-of-docetaxelinduced-neuropathy-and-impact-on-quality-of-life-among-breast-cancer-survivors(223cb0b9-a2be-4875-b1e0-a85114a8ea7d)/export.html
https://www.ncbi.nlm.nih.gov/pubmed/25541155
https://core.ac.uk/display/50706152
https://portal.findresearcher.sdu.dk/da/publications/223cb0b9-a2be-4875-b1e0-a85114a8ea7d
https://doi.org/10.1016/j.ejca.2014.11.024
https://portal.findresearcher.sdu.dk/da/publications/223cb0b9-a2be-4875-b1e0-a85114a8ea7d -
17
Autoren: et al.
Quelle: J Natl Cancer Inst
JNCI Journal of the National Cancer Institute; Vol 105Schlagwörter: Cyclophosphamide -- administration & dosage, Kaplan-Meier Estimate, Docetaxel, Taxoids -- administration & dosage, 0302 clinical medicine, Epirubicin -- administration & dosage, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms -- drug therapy -- genetics -- mortality -- pathology, Humanized -- therapeutic use, Tumor Markers, Early Detection of Cancer, Finland, Fluorouracil -- administration & dosage, Middle Aged, Prognosis, 3. Good health, Gene Expression Regulation, Neoplastic, Treatment Outcome, Lymphatic Metastasis, Female, Fluorouracil, Finland -- epidemiology, Biological -- genetics, Receptor, ErbB-2 -- genetics, Adult, Class I Phosphatidylinositol 3-Kinases, Molecular Sequence Data, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Article, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Predictive Value of Tests, Biomarkers, Tumor, Humans, Phosphatidylinositol 3-Kinases -- genetics, Cyclophosphamide, Neoplasm Staging, Proportional Hazards Models, Aged, Epirubicin, Neoplastic, Base Sequence, Gene Expression Profiling, Sciences biomédicales, Cancérologie, Gene Expression Regulation, Vinblastine -- administration & dosage -- analogs & derivatives, Mutation
Dateibeschreibung: 2 full-text file(s): application/pdf; application/pdf
Zugangs-URL: https://academic.oup.com/jnci/article-pdf/105/13/960/17312289/djt121.pdf
https://pubmed.ncbi.nlm.nih.gov/23739063
https://academic.oup.com/jnci/article/105/13/960/956263
https://core.ac.uk/display/34575079
https://minerva-access.unimelb.edu.au/handle/11343/263255
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/146371/Details
https://jnci.oxfordjournals.org/content/105/13/960.full.pdf
https://europepmc.org/articles/PMC3699437 -
18
Autoren: et al.
Quelle: Jensen, J D, Knoop, A, Laenkholm, A V, Grauslund, M, Jensen, M B, Santoni-Rugiu, E, Andersson, M & Ewertz, M 2012, ' PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab ', Annals of Oncology, vol. 23, no. 8, pp. 2034-42 . https://doi.org/10.1093/annonc/mdr546
Schlagwörter: Phosphatidylinositol 3-Kinases/genetics, Receptor, erbB-2, Class I Phosphatidylinositol 3-Kinases, Receptor, ErbB-2, Molecular Sequence Data, Epirubicin/administration & dosage, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Cyclophosphamide/administration & dosage, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, 0302 clinical medicine, Breast Neoplasms/drug therapy, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Phosphorylation, Humanized, Cyclophosphamide, Adjuvant, erbB-2, Epirubicin, Base Sequence, PTEN Phosphohydrolase, PTEN Phosphohydrolase/biosynthesis, Trastuzumab, Immunohistochemistry, 3. Good health, Survival Rate, ErbB-2/biosynthesis, Fluorouracil/administration & dosage, Chemotherapy, Adjuvant, Mutation, Humanized/administration & dosage, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Fluorouracil, Receptor
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/22172323
https://www.annalsofoncology.org/article/S0923-7534(19)38088-3/fulltext
https://academic.oup.com/annonc/article/23/8/2034/135228
https://pure-portal.regsj.dk/da/publications/pik3ca-mutations-pten-and-pher2-expression-and-impact-on-outcome-
https://www.sciencedirect.com/science/article/pii/S0923753419380883
https://paperity.org/p/40521382/pik3ca-mutations-pten-and-pher2-expression-and-impact-on-outcome-in-her2-positive-early
http://europepmc.org/abstract/MED/22172323
https://portal.findresearcher.sdu.dk/da/publications/9a10b59a-3d6c-4729-8828-df65a78ac610 -
19
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Clinical Trials. 9:408-417
Schlagwörter: Carcinoma, Hepatocellular, Epirubicin/administration & dosage, Antineoplastic Agents, Pilot Projects, Phase II as Topic/methods, Hepatocellular/therapy, 03 medical and health sciences, Clinical Trials, Phase II as Topic, 0302 clinical medicine, Randomized Controlled Trials as Topic/methods, Clinical Protocols, Electronic Health Records, Humans, Clinical Trials, Chemoembolization, Therapeutic, Epirubicin, Randomized Controlled Trials as Topic, Carcinoma, Liver Neoplasms, Liver Neoplasms/therapy, Antineoplastic Agents/administration & dosage, 3. Good health, Research Design, Critical Pathways, Chemoembolization, Cisplatin, Therapeutic/methods, Cisplatin/administration & dosage
Dateibeschreibung: application/pdf
Zugangs-URL: https://repository.kulib.kyoto-u.ac.jp/dspace/bitstream/2433/178667/1/1740774512445912.pdf
https://pubmed.ncbi.nlm.nih.gov/22605791
https://repository.kulib.kyoto-u.ac.jp/dspace/bitstream/2433/178667/1/1740774512445912.pdf
https://journals.sagepub.com/doi/abs/10.1177/1740774512445912
https://www.ncbi.nlm.nih.gov/pubmed/22605791
https://pubmed.ncbi.nlm.nih.gov/22605791/
http://journals.sagepub.com/doi/10.1177/1740774512445912
http://ctj.sagepub.com/lookup/doi/10.1177/1740774512445912 -
20
Autoren: et al.
Quelle: Journal of Theoretical Biology. 266:124-139
Schlagwörter: 0301 basic medicine, DNA-Binding Proteins -- genetics, Breast Neoplasms -- drug therapy, Neoplastic Stem Cells -- cytology -- drug effects, Gene Expression, Apoptosis, Breast Neoplasms, Gene Expression -- genetics, Cancer modeling, Models, Biological, Epirubicin -- administration & dosage -- pharmacology -- therapeutic use, Neoplasms -- drug therapy -- metabolism -- pathology, Cell Proliferation -- drug effects, Necrosis, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Models, Antigens, Neoplasm, Software Design, Neoplasms, Chemotherapy, Humans, Computer Simulation, Antigens, Precision Medicine, Cell Proliferation, Epirubicin, Clinical Trials as Topic, Cell Cycle, Biological, Individualized Medicine -- methods, Necrosis -- metabolism -- pathology, 3. Good health, Cancérologie, Apoptosis -- drug effects -- physiology, In silico oncology, DNA-Binding Proteins, Treatment Outcome, DNA Topoisomerases, Type II, Neoplastic Stem Cells, Female, Neoplasm -- genetics, Type II -- genetics, DNA Topoisomerases, Simulation, Algorithms, Cell Cycle -- drug effects -- physiology
Dateibeschreibung: 1 full-text file(s): application/pdf
Zugangs-URL: https://hal.archives-ouvertes.fr/hal-00613132/file/PEER_stage2_10.1016%252Fj.jtbi.2010.05.019.pdf
https://pubmed.ncbi.nlm.nih.gov/20515697
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/118214/Details
http://www.sciencedirect.com/science/article/pii/S0022519310002547
https://ui.adsabs.harvard.edu/abs/2010JThBi.266..124S/abstract
https://europepmc.org/article/MED/20515697
https://www.ncbi.nlm.nih.gov/pubmed/20515697
https://www.sciencedirect.com/science/article/pii/S0022519310002547
Nájsť tento článok vo Web of Science 
Full Text Finder